These other spin-off companies are also continuing in their successful paths on respective product commercialization.
|
Healionics Corporation
Healionics Corporation was formed in March 2007 to provide distinctive biomaterials solutions for research and medical device applications. Healionics has exclusive rights to a unique precision engineered angiogenic scaffold material developed by the University of Washington Engineered Biomaterials center (UWEB). Additionally, through an affiliate (RBG), Healionics has access to an extensive portfolio of other biomaterials, allowing it to potentially address a wide variety of medical applications. |
|
Inson Medical Systems Inc.
Inson Medical Systems Inc., forming in August 2007, is dedicated to novel drug delivery capabilities made possible with advanced biocompatible carrier materials and developments in self assembling molecular technology. Inson is initially focused on applications in areas such as chronic pain, where convenient and economical “on demand” treatment is needed, self-managed by the patient. Where the self-management is carried out within parameters pre-set by the patient’s physician. |
|
Calcionics Corporation
Calcionics Corporation, formed in July 2007, has licensed a method of use for the Osteopontin peptide. This peptide could provide therapeutics applicable to a wide range of cardiovascular and other conditions. Calcionics is developing compositions to inhibit calcification of bioprosthetic heart valves and treat hardening of natural vascular tissue. Pipeline opportunities include combinations with statins (a class of cholesterol lowering medications) and other established drug entities. |